VTYXVentyx Biosciences, Inc.

Nasdaq ventyxbio.com


$ 3.28 $ -0.03 (-0.76 %)    

Friday, 07-Jun-2024 15:59:54 EDT
QQQ $ 462.76 $ -0.41 (-0.09 %)
DIA $ 388.38 $ -0.84 (-0.22 %)
SPY $ 533.54 $ -0.65 (-0.12 %)
TLT $ 91.51 $ -1.71 (-1.83 %)
GLD $ 211.60 $ -7.83 (-3.57 %)
$ 3.26
$ 3.23
$ 0.00 x 0
$ 3.30 x 200
$ 3.04 - $ 3.36
$ 1.87 - $ 40.58
1,616,101
na
201.57M
$ 0.45
$ 561.46
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-09-2024 03-31-2024 10-Q
2 02-27-2024 12-31-2023 10-K
3 11-09-2023 09-30-2023 10-Q
4 08-10-2023 06-30-2023 10-Q
5 05-11-2023 03-31-2023 10-Q
6 03-23-2023 12-31-2022 10-K
7 11-04-2022 09-30-2022 10-Q
8 08-15-2022 06-30-2022 10-Q
9 05-12-2022 03-31-2022 10-Q
10 03-23-2022 12-31-2021 10-K
11 11-18-2021 09-30-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 oppenheimer-maintains-outperform-on-ventyx-biosciences-lowers-price-target-to-10

Oppenheimer analyst Jeff Jones maintains Ventyx Biosciences (NASDAQ:VTYX) with a Outperform and lowers the price target from...

 hc-wainwright--co-reiterates-neutral-on-ventyx-biosciences-maintains-6-price-target

HC Wainwright & Co. analyst Emily Bodnar reiterates Ventyx Biosciences (NASDAQ:VTYX) with a Neutral and maintains $6 pri...

 ventyx-biosciences-announces-preclinical-data-for-cns-penetrant-nlrp3-inhibitor-vtx3232-demonstrating-reversal-of-obesity-and-improvements-in-cardiometabolic-and-inflammatory-markers

VTX3232 demonstrated improvements in body weight, systemic inflammatory biomarkers and cardiometabolic parameters in diet-induc...

 ventyx-biosciences-appoints-matthew-moore-as-coo

Ventyx Biosciences, Inc. (NASDAQ:VTYX), ("Ventyx"), a clinical-stage biopharmaceutical company focused on advancing nov...

 ventyx-biosciences-q1-2024-gaap-eps-062-beats-067-estimate

Ventyx Biosciences (NASDAQ:VTYX) reported quarterly losses of $(0.62) per share which beat the analyst consensus estimate of $(...

 kura-sushi-posts-upbeat-sales-joins-caribou-biosciences-krispy-kreme-and-other-big-stocks-moving-higher-in-fridays-pre-market-session

U.S. stock futures were higher this morning, with the Dow futures gaining by around 100 points on Friday.

 canaccord-genuity-maintains-buy-on-ventyx-biosciences-lowers-price-target-to-15

Canaccord Genuity analyst Edward Nash maintains Ventyx Biosciences (NASDAQ:VTYX) with a Buy and lowers the price target from...

 wells-fargo-upgrades-ventyx-biosciences-to-overweight-raises-price-target-to-16

Wells Fargo analyst Derek Archila upgrades Ventyx Biosciences (NASDAQ:VTYX) from Equal-Weight to Overweight and raises the p...

 oppenheimer-upgrades-ventyx-biosciences-to-outperform-announces-12-price-target

Oppenheimer analyst Jeff Jones upgrades Ventyx Biosciences (NASDAQ:VTYX) from Perform to Outperform and announces $12 price ...

 dow-turns-higher-gds-holdings-shares-climb

U.S. stocks traded mixed toward the end of trading, with the Dow Jones index turning higher on Monday. The Dow traded up 0.08%...

 why-mesoblast-shares-are-trading-higher-by-13-here-are-other-stocks-moving-in-mondays-mid-day-session

Shares of Mesoblast Limited (NASDAQ: MESO) rose sharply during Monday’s session after the company announced FDA support of an ...

 canaccord-genuity-maintains-buy-on-ventyx-biosciences-lowers-price-target-to-16

Canaccord Genuity analyst Edward Nash maintains Ventyx Biosciences (NASDAQ:VTYX) with a Buy and lowers the price target from...

 crude-oil-edges-higher-lexicon-pharmaceuticals-shares-jump

U.S. stocks traded lower midway through trading, with the Dow Jones index dipping over 50 points on Monday. The Dow traded dow...

 whats-going-on-with-autoimmuneinflammatory-disorder-focused-ventyx-biosciences-on-monday

Ventyx Biosciences provides clinical and pipeline updates, revealing compelling results in NLRP3 inhibitor development. CEO Raj...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION